{"nctId":"NCT01421511","briefTitle":"TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections","startDateStruct":{"date":"2011-09-15","type":"ACTUAL"},"conditions":["Skin and Subcutaneous Tissue Bacterial Infections"],"count":666,"armGroups":[{"label":"TR-701 FA","type":"EXPERIMENTAL","interventionNames":["Drug: TR-701 FA"]},{"label":"Linezolid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Linezolid"]}],"interventions":[{"name":"TR-701 FA","otherNames":[]},{"name":"Linezolid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients requiring IV antibiotic therapy and with systemic signs of infection diagnosed with ABSSSI.\n* Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections\n\nExclusion Criteria:\n\n* Uncomplicated skin infections\n* Severe sepsis or septic shock\n* ABSSSI solely due to gram-negative pathogens","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Early Clinical Response Rate","description":"Responder: No increase in lesion surface area from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"283","spread":null},{"groupId":"OG001","value":"276","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at the End of Therapy Visit","description":"Responder: No increase in lesion surface area from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"289","spread":null},{"groupId":"OG001","value":"294","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at the End of Therapy Visit in the Clinically Evaluable at End of Therapy Analysis Set","description":"Responder: No increase in lesion surface area from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"272","spread":null},{"groupId":"OG001","value":"280","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Assessment of Clinical Success at the Post Treatment Evaluation Visit","description":"Clinical success defined as resolution/near resolution of disease specific signs and symptoms, absence/near resolution of baseline systemic signs of infection, and no further antibiotic therapy required for treatment of primary ABSSSI lesion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"292","spread":null},{"groupId":"OG001","value":"293","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Assessment of Clinical Success of the Post Therapy Evaluation Visit in Clinically Evaluable-Post Treatment Evaluation Analysis Set.","description":"Clinical success defined as resolution/near resolution of disease specific signs and symptoms, absence/near resolution of baseline systemic signs of infection, no new signs, symptoms or complications attributable to the ABSSSI and no further antibiotic therapy required for treatment of primary ABSSSI lesion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"268","spread":null},{"groupId":"OG001","value":"269","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Assessment of Clinical Response at the 48-72 Hour Visit","description":"Clinical improvement defined as improvement in overall clinical status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"304","spread":null},{"groupId":"OG001","value":"302","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Assessment of Clinical Response at the Day-7 Visit","description":"Clinical improvement defined as improvement in overall clinical status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"309","spread":null},{"groupId":"OG001","value":"308","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient-reported Pain, by Study Visit","description":"0=no pain, 10=worst pain Only 1 visit per participant for Day 4-6, only 1 visit for Day 7-9, and only 1 visit for Day 10-13.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"2.05"},{"groupId":"OG001","value":"-2.1","spread":"2.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"2.67"},{"groupId":"OG001","value":"-3.3","spread":"2.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"2.89"},{"groupId":"OG001","value":"-4.9","spread":"2.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"2.80"},{"groupId":"OG001","value":"-5.6","spread":"2.84"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":331},"commonTop":["Nausea","Headache","Diarrhoea","Vomiting","Abscess"]}}}